Venkatakrishnan, Karthik
EMD Serono, Inc.,
United States
2025 Rank: 272958
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 2212 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 272958 | 216690 |
| Total Cites | 434 | 542 |
| H-index | 9 | 10 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 47 | 47 |
| Total Cites to Single+First Authored Papers | 62 | 95 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 197 | 258 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 354 | 390 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.39 |
| Self-Citation Percentage |
19.93%
|
|
Venkatakrishnan, Karthik
EMD Serono, Inc.,
United States
2024 Rank: 272138
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 2200 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 272138 | 239041 |
| Total Cites | 350 | 438 |
| H-index | 7 | 8 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 44 | 44 |
| Total Cites to Single+First Authored Papers | 66 | 82 |
| Number of Single+First+Last Authored Papers | 88 | 88 |
| Total Cites to Single+First+Last Authored Papers | 144 | 197 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 292 | 318 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.38 |
| Self-Citation Percentage |
20.09%
|
|
Venkatakrishnan, Karthik
EMD Serono Research and Development Institute, Inc.,
United States
2023 Rank: 331665
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 2762 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 331665 | 260586 |
| Total Cites | 369 | 461 |
| H-index | 8 | 9 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 60 | 84 |
| Number of Single+First+Last Authored Papers | 85 | 85 |
| Total Cites to Single+First+Last Authored Papers | 151 | 209 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 302 | 334 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.38 |
| Self-Citation Percentage |
19.96%
|
|
Venkatakrishnan, Karthik
Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc.,
United States
2022 Rank: 160046
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1188 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 160046 | 173720 |
| Total Cites | 413 | 458 |
| H-index | 9 | 9 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 2 | 2 |
| Number of Single+First Authored Papers | 40 | 40 |
| Total Cites to Single+First Authored Papers | 84 | 97 |
| Number of Single+First+Last Authored Papers | 74 | 74 |
| Total Cites to Single+First+Last Authored Papers | 169 | 193 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 309 | 330 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.39 |
| Self-Citation Percentage |
9.83%
|
|
Venkatakrishnan, Karthik
Takeda Oncology,
United States
2021 Rank: 247479
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1967 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 247479 | 223153 |
| Total Cites | 585 | 656 |
| H-index | 12 | 14 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 115 | 133 |
| Number of Single+First+Last Authored Papers | 69 | 69 |
| Total Cites to Single+First+Last Authored Papers | 231 | 263 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 446 | 481 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.36 |
| Self-Citation Percentage |
10.82%
|
|
Venkatakrishnan, Karthik
Takeda Pharmaceutical Company Limited,
United States
2020 Rank: 179418
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1253 out of 94611 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 179418 | 154852 |
| Total Cites | 431 | 536 |
| H-index | 10 | 11 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 2 | 2 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 83 | 105 |
| Number of Single+First+Last Authored Papers | 61 | 61 |
| Total Cites to Single+First+Last Authored Papers | 160 | 206 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 329 | 365 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.47 |
| Self-Citation Percentage |
19.59%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.